A trial led by Professor Jeremy Chataway (UCL Queen Square Institute of Neurology) and Professor Max Parmar (MRC Clinical Trials Unit at UCL) will combine existing drugs to assess whether drugs already on the market can prevent multiple sclerosis (MS) from worsening over time.
Read: Guardian
Close
